Showing 71-80 of 1560 results for "".
Operational Considerations for Bispecific T-Cell Engager Therapies
https://reachmd.com/programs/medical-industry-feature/operational-considerations-for-bispecific-t-cell-engager-therapies/33005/In recent years, bispecific T-cell engager therapies have emerged as an innovative approach for treating cancer by directing the patient’s own T-cells to target tumor‑associated antigens on cancer cells.1 However, the implementation of bispecific T-cell engager therapies into clinical practice comeIslet Cell Transplant for Diabetics
https://reachmd.com/programs/clinicians-roundtable/islet-cell-transplant-for-diabetics/1748/In this segment, host Dr. Mark Nolan Hill speaks with Dr. Berhard Hering, international expert in islet cell transplants. Dr. Hering explains the promising new procedure offering diabetics the hope of being insulin free.Raising Awareness of Sickle Cell Disease
https://reachmd.com/programs/everyday-family-medicine/raising-awareness-of-sickle-cell-disease/10357/Although there’s currently no cure for sickle cell disease, there are things we can ALL do to help these patients.Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms
https://reachmd.com/programs/dermconsult/cannabis-extract-and-melanoma-insights-into-cell-death-mechanisms/17998/Researchers have started looking into how a Cannabis sativa extract, called PHEC-66, could trigger cell death in melanoma cells.Targeting Senescent Cells
https://practicaldermatology.com/series/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseasesEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urFDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
https://reachmd.com/programs/FDA-Drug-Information-Updates/fda-disco-l-glutamine-sickle-cell-disease/9773/FDA medical oncologists discuss the approval of l-glutamine to reduce the acute complications of sickle cell disease.A Way to Boost Cancer Cell Vulnerability to Chemotherapy
https://reachmd.com/programs/focus-on-cancer/a-way-to-boost-cancer-cell-vulnerability-to-chemotherapy/4253/Cancer cells can be made to become more vulnerable to treatments like chemotherapy, and there are therapeutics under development which are designed to impact this so-called microenvironment of tumor cells. John Docherty, president of Toronto-based Helix BioPharma, tells host Bruce Japsen about a neCAR T-Cell Therapy: New Frontiers in Diffuse Systemic Sclerosis Treatment
https://reachmd.com/programs/living-rheum/car-t-cell-therapy-new-frontiers-in-diffuse-systemic-sclerosis-treatment/30073/CD19-targeted CAR T-cell therapy may offer lasting benefits for diffuse systemic sclerosis. Here’s what you should know.FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
https://reachmd.com/programs/project-oncology/fda-disco-avelumab-merkel-cell-carcinoma/9777/FDA oncologists discuss the approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.